摘要
背景:褪黑素是一种具有许多适用于治疗神经疾病的特性的分子。这些性质包括以下:氧和氮反应性物质的有效清除剂,抗炎症特征,免疫增强性质和昼夜节律性的调节。此外,神经疾病和精神障碍患者通常会发现低浓度的褪黑激素。在包括神经系统疾病(例如,阿尔茨海默氏病,帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿舞蹈病,癫痫症,头痛等)的各种病理学的实验模型中获得的阳性结果为以及心理和行为上的混乱(例如,自闭症谱系障碍,注意力缺陷多动障碍等),已经作为设计临床试验来研究褪黑激素在人类病理学中可能有用的基础,尽管从实验室工作台并不总是适用于病人的床边。 目的:在本文中,我们回顾那些描述在神经病理学领域中用于各种治疗目的的褪黑素给药的结果的论文。 结论:强烈的方法和适当剂量的褪黑激素的临床试验是必要的,以支持或拒绝褪黑素在神经系统疾病的有效性
关键词: 褪黑激素,阿尔茨海默病; 帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿病,自闭症谱系障碍,注意力缺陷多动症,头痛,癫痫,脊髓损伤,缺血性中风,睡眠障碍。
Current Medicinal Chemistry
Title:Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Volume: 24 Issue: 35
关键词: 褪黑激素,阿尔茨海默病; 帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿病,自闭症谱系障碍,注意力缺陷多动症,头痛,癫痫,脊髓损伤,缺血性中风,睡眠障碍。
摘要: Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Export Options
About this article
Cite this article as:
Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders, Current Medicinal Chemistry 2017; 24 (35) . https://dx.doi.org/10.2174/0929867324666170718105557
DOI https://dx.doi.org/10.2174/0929867324666170718105557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Editorial
Drug Delivery Letters Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Drug Repositioning: Antimalarial Activities of GABA Analogs in Mice Infected with <i>Plasmodium berghei</i>
Central Nervous System Agents in Medicinal Chemistry Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Synthesis and Evaluation of Anticonvulsant Activities of Triazole- Incorporated Benzothiazoles
Letters in Drug Design & Discovery Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics